Newest figures come from the 10-Q for Q1 FY2026, filed May 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SLNO SEC filings page.
Soleno Therapeutics, Inc. (SLNO) reported $190.4M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Soleno shifted from development-stage losses to positive earnings and cash generation, while selling costs remain the largest reported operating burden.
In FY2025, operating cash flow of$46.8M exceeded net income of$20.9M , indicating earnings converted into cash unusually well. Free cash flow of$46.7M nearly matched operating cash flow because capital expenditures were only$73K , so little cash was absorbed by physical reinvestment.
After FY2024's net loss of
Current liabilities increased
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Soleno Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Soleno Therapeutics, Inc. scores 48/100 on it among other operating companies.
Not available for Soleno Therapeutics, Inc., so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.
Soleno Therapeutics, Inc. held more cash than long-term debt at the end of fiscal year 2025, with $70.1M of cash against $49.9M of long-term debt. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Soleno Therapeutics, Inc. scores 93/100 among other operating companies measured the same way.
Soleno Therapeutics, Inc. held $5.80 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 5.80. Liquidity ranks operating companies on that ratio, and Soleno Therapeutics, Inc. scores 93/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Soleno Therapeutics, Inc. scores 91/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Soleno Therapeutics, Inc. scores 20/100 on it among other operating companies.
Soleno Therapeutics, Inc. passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Soleno Therapeutics, Inc. generates $2.24 in operating cash flow ($46.8M OCF vs $20.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Soleno Therapeutics, Inc. earns $1.72 in operating income for every $1 of interest expense ($9.4M vs $5.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Soleno Therapeutics, Inc. generated $94.6M in revenue in Q1 2026.
Soleno Therapeutics, Inc.'s EBITDA was $31.8M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 20.7%.
Soleno Therapeutics, Inc. reported $31.4M in net income in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 27.6%.
Soleno Therapeutics, Inc. earned $0.59 per diluted share (EPS) in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 29.8%.
Cash & Balance Sheet
Soleno Therapeutics, Inc. generated $25.9M in free cash flow in Q1 2026, representing cash available after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 46.7%.
Soleno Therapeutics, Inc. held $133.0M in cash against $49.9M in long-term debt as of Q1 2026.
Not reported for Q1 2026.
Margins & Returns
Soleno Therapeutics, Inc.'s gross margin was 98.7% in Q1 2026, indicating the percentage of revenue retained after direct costs.
Soleno Therapeutics, Inc.'s operating margin was 33.1% in Q1 2026, reflecting core business profitability.
Soleno Therapeutics, Inc.'s net profit margin was 33.2% in Q1 2026, showing the share of revenue converted to profit.
Soleno Therapeutics, Inc.'s quarterly ROE was 6.3% in Q1 2026: one quarter's net income over shareholder equity, not annualized. This is up 25.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.3 percentage points.
Capital Allocation
Soleno Therapeutics, Inc. invested $11.3M in research and development in Q1 2026. This represents a decrease of 16.6% from the same quarter a year earlier. Against the prior quarter it is up 18.0%.
Soleno Therapeutics, Inc. spent $4K on share buybacks in Q1 2026, returning capital to shareholders by reducing shares outstanding. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Soleno Therapeutics, Inc. invested $40K in capex in Q1 2026, funding long-term assets and infrastructure. This represents an increase of 700.0% from the same quarter a year earlier. Against the prior quarter it is down 31.0%.
SLNO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $94.6M | N/A | $66.0M | $32.7M | N/A | N/A | N/A | N/A |
| Cost of Revenue | $1.2M | N/A | $1.1M | $696K | N/A | N/A | N/A | N/A |
| Gross Profit | $93.4M | N/A | $64.9M | $32.0M | N/A | N/A | N/A | N/A |
| R&D Expenses | $11.3M-16.6% | $9.6M-55.5% | $8.4M-72.1% | $9.1M-25.9% | $13.5M-7.4% | $21.5M+147.3% | $30.1M+398.7% | $12.3M+140.1% |
| SG&A Expenses | $50.4M+72.1% | $40.9M+9.6% | $33.8M-31.4% | $28.2M+159.3% | $29.3M+245.4% | $37.3M+801.0% | $49.2M+1382.7% | $10.9M+243.6% |
| Operating Income | $31.3Mn/m | $39.6Mn/m | $22.1Mn/m | -$6.5Mn/m | -$45.7Mn/m | -$59.1Mn/m | -$80.2Mn/m | -$24.9Mn/m |
| EBITDA | $31.8Mn/m | $40.1Mn/m | $22.6Mn/m | -$6.0Mn/m | -$45.2Mn/m | -$58.6Mn/m | -$79.7Mn/m | -$24.4Mn/m |
| Interest Expense | $1.3M-5.1% | $1.3M | $1.4M | $1.4M | $1.4M | N/A | N/A | N/A |
| Income Tax | $3.5Mn/m | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Net Income | $31.4Mn/m | $43.4Mn/m | $26.0Mn/m | -$4.7Mn/m | -$43.8Mn/m | -$56.0Mn/m | -$76.6Mn/m | -$21.9Mn/m |
| EPS (Basic) | $0.60n/m | $0.85n/m | $0.49n/m | -$0.09n/m | -$0.95n/m | -$1.30 | -$1.83 | -$0.57 |
| EPS (Diluted) | $0.59n/m | $0.84n/m | $0.47n/m | -$0.09n/m | -$0.95n/m | -$1.30 | -$1.83 | -$0.57 |
| Diluted Shares (Avg) | 53M+14.9% | N/A | 55M+31.1% | 50M+30.7% | 46M+27.5% | N/A | 42M | 39M |
SLNO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'2410-K | Q3'2410-Q | Q2'24Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $608.4M+91.3% | $563.8M+70.4% | $599.9M+102.2% | $332.3M+9.3% | $318.1M+88.4% | $331.0M+83.2% | $296.7M+366.9% | $304.1M+882.8% |
| Current Assets | $326.4M+5.7% | $355.8M+21.1% | $534.9M+107.1% | $316.8M+18.4% | $308.9M+104.3% | $293.9M+71.5% | $258.2M+381.2% | $267.5M+1205.0% |
| Cash & Equivalents | $133.0M+63.6% | $70.1M-20.3% | $246.7M+409.5% | $76.5M+34.1% | $81.3M+89.8% | $87.9M-48.2% | $48.4M-7.7% | $57.0M+194.4% |
| Short-Term Investments | $122.6M-41.2% | $235.4M+15.7% | $252.3M+21.1% | $210.3M+0.6% | $208.6M+95.4% | $203.5Mn/m | $208.4Mn/m | $209.1Mn/m |
| Inventory | $17.3M | $15.0M | $6.7M | $2.4M | N/A | N/A | N/A | N/A |
| Accounts Receivable | $47.1M | $28.2M | $25.5M | $24.6M | N/A | N/A | N/A | N/A |
| Long-Term Investments | $273.4Mn/m | $200.6M+637.3% | $57.1M+104.5% | $7.0M-75.4% | $0-100.0% | $27.2Mn/m | $27.9Mn/m | $28.5Mn/m |
| Total Liabilities | $112.6M+31.2% | $113.7M+32.4% | $105.1M+228.3% | $92.2M+294.3% | $85.8M+237.2% | $85.9M+270.3% | $32.0M-20.6% | $23.4M+26.2% |
| Current Liabilities | $58.0M+269.0% | $61.4M+227.3% | $33.3M+122.2% | $20.9M+128.9% | $15.7M+16.8% | $18.7M+62.9% | $15.0M-48.4% | $9.2M+4.0% |
| Non-Current Liabilities | $54.5M-22.2% | $52.4M-22.0% | $71.8M+321.5% | $71.2M+400.7% | $70.1M+484.8% | $67.1M+474.6% | $17.0M+50.4% | $14.2M+46.3% |
| Long-Term Debt | $49.9M+0.1% | $49.9M+0.1% | $49.9M | $49.8M | $49.8M | $49.8M | N/A | N/A |
| Total Equity | $495.8M+113.5% | $450.1M+83.6% | $494.8M+86.9% | $240.1M-14.5% | $232.3M+62.0% | $245.1M+55.6% | $264.7M+1040.0% | $280.8M+2159.4% |
| Retained Earnings | -$400.0Mn/m | -$431.4Mn/m | -$474.7Mn/m | -$500.7Mn/m | -$496.0Mn/m | -$452.3Mn/m | -$396.3Mn/m | -$319.7Mn/m |
Not reported in any period shown, so not listed: Goodwill.
SLNO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $26.0Mn/m | $48.7Mn/m | $43.5Mn/m | -$12.6Mn/m | -$32.8Mn/m | -$24.0Mn/m | -$14.9Mn/m | -$17.7Mn/m |
| Depreciation & Amortization | $514K+2.0% | $509K+1.2% | $502K+0.4% | $502K+1.6% | $504K+2.9% | $503K+2.9% | $500K+2.0% | $494K+1.0% |
| Stock-Based Compensation | $16.1M+9.4% | N/A | $10.0M-82.3% | $9.7M+35.4% | $14.7M+127.8% | N/A | $56.6M+2471.5% | $7.2M+494.7% |
| Capital Expenditures | $40K+700.0% | $58K+625.0% | $1K-99.5% | $9K+12.5% | $5K-54.5% | $8Kn/m | $191Kn/m | $8Kn/m |
| Free Cash Flow | $25.9Mn/m | $48.6Mn/m | $43.5Mn/m | -$12.6Mn/m | -$32.8Mn/m | -$24.0Mn/m | -$15.1Mn/m | -$17.7Mn/m |
| Investing Cash Flow | $38.0M+65.6% | -$125.4M-2045.7% | -$91.4M-2363.4% | -$7.9Mn/m | $22.9Mn/m | $6.4Mn/m | $4.0Mn/m | -$120.9Mn/m |
| Financing Cash Flow | -$1.0M-132.4% | -$99.9M-275.1% | $218.2M+9489.2% | $15.7M-89.7% | $3.2M+243.1% | $57.1M-53.8% | $2.3M-94.2% | $152.7M+795.4% |
| Share Buybacks | $4Kn/m | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
SLNO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.7% | N/A | 98.3% | 97.9% | N/A | N/A | N/A | N/A |
| Operating Margin | 33.1% | N/A | 33.5% | -20.0% | N/A | N/A | N/A | N/A |
| Net Margin | 33.2% | N/A | 39.4% | -14.4% | N/A | N/A | N/A | N/A |
| Return on Equity | 6.3%+25.2pp | 9.6%+32.5pp | 5.3%+34.2pp | -2.0%+5.8pp | -18.9%-3.9pp | -22.8%-15.7pp | -28.9%+17.8pp | -7.8%+60.4pp |
| Return on Assets | 5.2%+18.9pp | 7.7%+24.6pp | 4.3%+30.2pp | -1.4%+5.8pp | -13.8%-1.1pp | -16.9%-10.7pp | -25.8%-8.7pp | -7.2%+20.2pp |
| Current Ratio | 5.62-14.0x | 5.80-9.9x | 16.08-1.2x | 15.13-14.1x | 19.64+8.4x | 15.68+0.8x | 17.26+15.4x | 29.24+26.9x |
| Debt-to-Equity | 0.10-0.1x | 0.11-0.1x | 0.10 | 0.21 | 0.21 | 0.20 | N/A | N/A |
| Liabilities-to-Equity | 0.23-0.1x | 0.25-0.1x | 0.21+0.1x | 0.38+0.3x | 0.37+0.2x | 0.35+0.2x | 0.12-1.6x | 0.08-1.4x |
| Asset Turnover | 0.16 | N/A | 0.11 | 0.10 | N/A | N/A | N/A | N/A |
| FCF Margin | 27.4% | N/A | 65.8% | -38.6% | N/A | N/A | N/A | N/A |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Soleno Therapeutics, Inc. SLNO | FY2025 | $190.4M | $20.9M | 11.0% | N/A | 69/100 |
| Minerva Neurosciences, Inc NERV | FY2025 | N/A | -$293.4M | N/A | $99.7M | — |
| uniQure N.V. QURE | FY2025 | $16.1M | -$199.0M | N/A | $1.4B | 58/100 |
| Zevra Therapeutics, Inc. ZVRA | FY2025 | $106.5M | $83.2M | 78.2% | $521.3M | 48/100 |
| Altimmune, Inc. ALT | FY2025 | $41K | -$88.1M | N/A | $258.8M | — |
| BridgeBio Pharma, Inc. BBIO | FY2025 | $502.1M | -$724.9M | N/A | $14.8B | 61/100 |
Where Soleno Therapeutics, Inc. Ranks
Frequently Asked Questions
Soleno Therapeutics, Inc. (SLNO) reported $190.4M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Yes, Soleno Therapeutics, Inc. (SLNO) reported a net income of $20.9M in fiscal year 2025, with a net profit margin of 11.0%.
Soleno Therapeutics, Inc. (SLNO) had EBITDA of $11.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Soleno Therapeutics, Inc. (SLNO) had $70.1M in cash and equivalents against $49.9M in long-term debt.
Soleno Therapeutics, Inc. (SLNO) had a gross margin of 98.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Soleno Therapeutics, Inc. (SLNO) had an operating margin of 4.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Soleno Therapeutics, Inc. (SLNO) had a net profit margin of 11.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Soleno Therapeutics, Inc. (SLNO) has a return on equity of 4.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Soleno Therapeutics, Inc. (SLNO) generated $46.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Soleno Therapeutics, Inc. (SLNO) generated $46.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Soleno Therapeutics, Inc. (SLNO) had $563.8M in total assets as of fiscal year 2025, including both current and long-term assets.
Soleno Therapeutics, Inc. (SLNO) invested $73K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Soleno Therapeutics, Inc. (SLNO) invested $40.6M in research and development during fiscal year 2025.
Soleno Therapeutics, Inc. (SLNO) had a current ratio of 5.80 as of fiscal year 2025, which is generally considered healthy.
Soleno Therapeutics, Inc. (SLNO) had a debt-to-equity ratio of 0.11 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Soleno Therapeutics, Inc. (SLNO) had a liabilities-to-equity ratio of 0.25 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Soleno Therapeutics, Inc. (SLNO) had a return on assets of 3.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Soleno Therapeutics, Inc. (SLNO) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Soleno Therapeutics, Inc. (SLNO) has an earnings quality ratio of 2.24x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Soleno Therapeutics, Inc. (SLNO) has an interest coverage ratio of 1.72x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Soleno Therapeutics, Inc. (SLNO) scores 69 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Soleno Therapeutics, Inc. it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.